TScan Therapeutics hangs around $1.08; eyes on next week
TScan Therapeutics heads into June as investors wait for the next clinical update. Shares ended Friday at $1.08, with trading volume light ahead of the weekend and U.S. markets closed. The stock moved between $1.04 and $1.13 through the shortened week, historical data from the company showed. TScan is flagging early data for Cohort C in its ALLOHA Phase 1 blood-cancer trial for the second quarter and also says it wants to start a Phase 3 trial of TSC-101 in that same quarter. A Phase 3 trial is late-stage and usually backs a regulatory filing.